Application of methylation modification of long-chain non-coding RNA in treatment of rheumatoid arthritis

By studying the methylation modification and FTO binding of long-chain non-coding RNA ENST00000619282, it was discovered that its potential to inhibit apoptosis in rheumatoid arthritis, providing a new target for the treatment of RA and solving the apoptosis-related RA cell Treatment problems significantly reduce RA cell apoptosis and promote the treatment direction of rheumatoid arthritis.

CN119074757APending Publication Date: 2024-12-06FIRST AFFILIATED HOSPITAL OF ANHUI UNIV OF CHINESE MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411251738.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-09
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The pathogenesis of rheumatoid arthritis is not fully understood. Without special treatments, it is difficult for the existing technology to effectively solve the therapeutic targets related to RA cell apoptosis.

Method used

By studying the methylation modification of long-chain non-coding RNA ENST00000619282, it was determined that its binding to the demethylation transferase FTO and inhibited cell apoptosis. It was found that this lncRNA has the potential to become a new target for RA cell apoptosis and through drugs Intervention reduces its expression to inhibit apoptosis of RA cells.

Benefits of technology

In experimental and clinical validation, methylation modification of ENST00000619282 is involved in the pathogenesis of RA cell apoptosis, and significantly reduces RA cell apoptosis by intervening in its expression, providing a new potential drug target for the treatment of RA.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119074757A_ABST
    Figure CN119074757A_ABST
Patent Text Reader

Abstract

The invention discloses an application of methylation modification of long-chain non-coding RNA (Ribonucleic Acid) in treatment of rheumatoid arthritis. The long-chain non-coding lncRNA ENST00000619282 is combined with a target protein PUF60 under the modification of demethylated transferase (FTO), so that the cell apoptosis is inhibited. On the basis of the lncRNA ENST00000619282 found by a whole transcriptome high-throughput sequencing technology, it is proved that the lncRNA ENST00000619282 is combined with demethylated transferase FTO to achieve methylation modification of RNA, acts on a target gene PUF60 and inhibits RA cell apoptosis, and therefore it is proved that the lncRNA ENST00000619282 can be used for preparing the medicine for treating RA cell apoptosis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of molecular biology of rheumatoid arthritis, and specifically relates to the application of methylation modification of long-chain non-coding RNA in the treatment of rheumatoid arthritis. Background Art

[0002] Rheumatoid arthritis (RA) is a chronic, inflammatory, progressive, autoimmune disease with a high incidence and disability rate, involving multiple systemic lesions, a lingering course of disease that is difficult to cure, and a reduced quality of life for patients. The global incidence of RA is approximately 0.3%-1%, and the incidence in women is higher than that in men, with a male-to-female ratio of approximately 1:3. Its exact pathogenesis is not yet fully understood, and there is still a lack of specific clinical treatments. Therefore, exploring the pathogenesis of RA and new potential therapeutic targets, and finding effective drugs for RA, have great practical value and high social benefits.

[0003] Long non-coding RNA (lncRNA) is a type of RNA with a length of more than 200 nt and does not encode proteins. It can regulate gene expression at the epigenetic, transcriptional and post-transcriptional levels, and participate in multiple biological processes such as proliferation, apoptosis and oxidative stress in various diseases including RA. 6-Methyladenine (N6-methyladenosine, m6A) modification refers to the sixth N atom of base A. It is one of the most common modifications of eukaryotic mRNA and lncRNA. It participates in the pathogenesis of RA by promoting precursor RNA splicing, mRNA translation and enhancing RNA stability. It is currently a hot spot and difficulty in RNA epigenetics and has attracted widespread attention from scholars at home and abroad. As the main demethylase for m6A modification, obesity-related protein (FTO) is located in the cell nucleus and can bind to and demethylate various types of RNA, such as mRNA, snRNA and tRNA. When FTO plays a demethylating role, the original site of m6A modification cannot be recognized by m6A binding proteins, thereby affecting RNA splicing, maturation, translation or degradation.

[0004] Abnormal proliferation of synovial tissue and infiltration of inflammatory cells are important pathological features of RA. Fibroblast-like synoviocytes (FLS) are an important component of synovial tissue and are key effector cells in the pathogenesis of RA. They have invasive effects similar to tumor cells. Cell apoptosis escape is an important cause of RA. FLS can also secrete a large number of inflammatory cytokines, destroy RA bone, and ultimately lead to joint deformity and dysfunction. Therefore, exploring the methylation modification of lncRNA related to RA inflammation or apoptosis has great clinical application value for explaining the pathogenesis of RA. Summary of the invention

[0005] The present invention obtains the methylation-modified transferase FTO of lncRNA, namely lncRNAENST00000619282, through experimental research, determines that ENST00000619282m6A modification is related to cell apoptosis, and finds through experimental research technology that the lncRNA binding protein has the potential to become a new target for promoting RA cell apoptosis.

[0006] The technical solution adopted by the present invention is:

[0007] First, the present invention proposes an application of methylation modification of long non-coding RNA in the treatment of rheumatoid arthritis, wherein the long non-coding RNA is lncRNA ENST00000619282.

[0008] Secondly, the present invention also proposes an application of the methylation modification of the long non-coding RNA in the preparation of a drug for treating rheumatoid arthritis. Specifically, the methylation modification of the long non-coding RNA can be used to prepare a drug for treating RA cell apoptosis, and the lncRNA ENST00000619282 can bind to the target protein PUF60 under the modification of the demethyltransferase FTO, thereby inhibiting cell apoptosis.

[0009] Specifically, the present invention first predicts that ENST00000619282 has two methylation modification sites through SRAMP (http: / / www.cuilab.cn / sramp); the m6A level in RA peripheral blood mononuclear cells (PBMCs) and FLS co-cultured cells (referred to as co-cultured cells) is reduced by colorimetry; RT-qPCR detection shows that the RNA expression of FTO and ENST00000619282 in co-cultured cells is increased; WB detection shows that the protein expression of FTO in co-culture is increased; after interfering with FTO, the expression of ENST00000619282 is reduced; MeRIP-qPCR detection shows that the expression of ENST00000619282m6A in co-cultured cells is reduced. At the same time, after silencing FTO through the actinomycin D experiment, the half-life of lncRNAENST00000619282mRNA is shortened and the stability is reduced. After overexpressing FTO, lncRNAENST00000619282 has stronger stability. Interference with ENST00000619282 decreased the expression of pro-apoptotic protein Bax and increased the expression of anti-apoptotic protein Bcl-2; overexpression of ENST00000619282 increased the expression of pro-apoptotic protein Bax and decreased the expression of anti-apoptotic protein Bcl-2. In addition, the present invention also determined PUF60 as the downstream target gene of lncRNAENST00000619282 through RNA pull down experimental technology.

[0010] In addition, the present invention also verified in clinical practice that the expression of ENST00000619282 was elevated in RA patients, and correlation analysis showed that FTO was positively correlated with ENST00000619282. After intervention with the in-hospital Chinese medicine compound Xinfeng Capsule (XFC), the expression of ENST00000619282 decreased.

[0011] Therefore, the present study suggests that lncRNA ENST00000619282 methylation is involved in the pathogenesis of RA cell apoptosis and has the potential to become a new target for promoting RA cell apoptosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0012] Figure 1 Methylation site prediction for ENST00000619282.

[0013] Figure 2 is the m6A level in co-cultured cells.

[0014] Figure 3 The expression of FTO and ENST00000619282 in co-cultured cells.

[0015] Figure 4 The expression of ENST00000619282m6A in co-cultured cells.

[0016] Figure 5 These are the results of the actinomycin D experiment.

[0017] Figure 6 The effect of ENST00000619282 on cell apoptosis.

[0018] Figure 7 These are the results of RNA pull down experiments.

[0019] Figure 8 The results of clinical trials. DETAILED DESCRIPTION

[0020] The experimental methods in the following examples without specifying specific conditions are usually carried out according to conventional conditions or conditions recommended by the manufacturer.

[0021] Example 1 Methylation modification of ENST00000619282 and its effect on apoptosis

[0022] 1. Extraction of peripheral blood mononuclear cells (PBMCs) from RA patients

[0023] Use EDTA anticoagulant tubes to collect 5 mL of venous blood from RA patients, and mix PBS and anticoagulant blood in a 1:1 ratio gently; slowly drip the diluted sample onto the Ficoll-Paque separation solution in a 15 mL centrifuge tube, and centrifuge at 3000 rpm for 35 min; after centrifugation, layers appear, from top to bottom: plasma layer, PBMCs layer, Ficoll-Paque PLUS, red blood cell layer, and use a dropper to gently aspirate the PBMCs in the middle; add 3 times PBS, mix well, centrifuge at 1000 rpm for 10 min, and discard the supernatant; repeat twice, add 1 mL PBS to resuspend the cells, transfer to a 1.5 mL EP tube, and store for later use.

[0024] 2. Isolation, identification, preparation and cultivation of RA-FLS

[0025] Tissues of the knee joints of patients undergoing RA surgery were taken and soaked in 75% alcohol for about 2 minutes. The tissue blocks were cut into squares with a side length of about 0.1 cm, placed in 2 mL of fibroblast complete medium, infiltrated into tissue blocks, and placed in a 5% CO2 cell culture incubator. After the cells growing around the tissue blocks merged into a sheet, the cells were digested with trypsin. After the cells climbed the slice, 50 μL of primary antibody was taken on a waterproof membrane, and the secondary antibody (secondary antibody: PBS = 1:500) was incubated at room temperature in the dark for 2 hours, then washed with PBS 3×5 minutes / time, stained with DAPI (DAPI: PBS = 1:1000) for 5 minutes, washed with PBS 3×5 minutes / time, and 1 drop of Fluoromount-G was dropped on each slide, and the side with cells was covered to identify the cells as P1 generation cells. The cells were inoculated into a 6-well plate, and the number of cells per well was about 1×10 5 Fresh culture medium containing different concentrations of puromycin (1ug / mL, 2ug / mL, 3ug / mL, 4ug / mL, 5ug / mL, 6ug / mL, 7ug / mL) was added to a 24-well plate with cells to screen the lowest concentration. The result showed that the concentration of puromycin was 1ug / mL. The preparation of the RA-FLS immortalized cell line was completed, and the cells were allowed to fuse with a purity of more than 95% for subsequent experiments.

[0026] 3. Co-culture of RA-PBMCs and RA-FLS (hereinafter referred to as co-culture cells)

[0027] Take the spare RA-FLS, digest the RA-FLS cells with 0.25% trypsin, and then blow them into single suspended cells, centrifuge at 1000rpm for 15min, add DMEM culture medium and blow and mix, adjust the RA-FLS cell count to the number required for the experiment, and add them to the lower chamber of the Transwell chamber; take the spare RA-PBMCs, centrifuge, add the RA-PBMCs to the upper chamber of the Transwell chamber, co-culture the RA-PBMCs and RA-FLS, and collect the RA-FLS after co-culture for subsequent experimental detection.

[0028] 4. Colorimetric Detection of Overall mA Levels in Co-cultured Cells

[0029] Prepare cells, EpiQuik TM The m6A RNA Methylation Quantification Kit was used to detect the overall m6A level in co-cultured cells.

[0030] 5. RNA extraction and RT-qPCR detection

[0031] RNA was extracted from the co-cultured cells according to the instructions of TRIzol Reagent (Invitrogen). After reverse transcription, RT-qPCR was performed using PrimeScript RT-PCR Kit (Takara). The operation was carried out according to the instructions of the kit (β-actin was used as an internal reference). The PCR reaction program was as follows: Stage 1: 95°C 30s, Stage 2 (Cycle: 40): 95°C 15s, 60°C 30s.

[0032] The primer information for each detection index in the RT-qPCR experiment is as follows:

[0033]

[0034] 6. Western blot detection of FTO and apoptosis protein expression

[0035] The cell supernatant was collected, and RIPA cell lysis buffer was added to extract the total protein in the co-cultured cells for protein quantification; samples were added, electrophoresed, and transferred to the membrane at a constant flow rate; 5% skim milk powder was used for blocking at room temperature for 2 h; after washing, FTO (goat anti-rabbit, 1:1000), Bax (goat anti-rabbit, 1:500), and Bcl-2 (goat anti-mouse, 1:1000) primary antibodies were added, and the cells were incubated at 4°C with slow shaking overnight; after washing, the secondary antibody (horseradish peroxidase labeled) was diluted at a ratio of 1:10000 and incubated at room temperature for 2 h; after washing, ECL color development was performed, and the cells were exposed, fixed, and photographed in a darkroom, and the ratio of the absorbance value of the target protein to that of β-actin was calculated.

[0036] 7. Co-culture Cell Transfection

[0037] Small molecule RNA transfection: Use LipofectamineTM RNAiMAX to transfer siRNA (final concentration: 100 nM) into the co-culture, replace with complete culture medium on the second day, and perform subsequent experiments as needed.

[0038] Plasmid DNA transfection: first inoculate cells as required, and when the co-culture density reaches more than 85%, use LipofectamineTM2000 to evenly add pcDNA3.1-NC and pcDNA3.1-ENST00000619282 into the cell culture medium at a concentration ratio of lip3000: plasmid = 2μL:1μg, mix gently, and replace with new complete culture medium after 4-6 hours, and conduct subsequent experiments as needed.

[0039] 8. Actinomycin D validation ENST00000619282 stability

[0040] The treated cells were collected, and the cells were treated with 4uM actinomycin D for 0h, 2h, 4h and 8h. The cells were collected at different time points, and the RNA of each group was extracted for qPCR detection.

[0041] The experimental results show that:

[0042] Figure 1 Methylation site prediction for ENST00000619282 ( Figure 1 A), and it was predicted that ENST00000619282 had two highly methylated sites ( Figure 1 B).

[0043] Figure 2 The m6A level in co-cultured cells was determined by colorimetry, and the m6A level in co-cultured cells was reduced.

[0044] Figure 3 The expression of FTO and ENST00000619282 in co-cultured cells was detected by RT-qPCR, and the RNA expression of FTO and ENST00000619282 in co-cultured cells was increased ( Figure 3 A, 3D); WB detection showed that the protein expression of FTO increased in co-culture ( Figure 3 B, 3C); After interfering with FTO, the expression of ENST00000619282 was reduced ( Figure 3 E).

[0045] Figure 4 The expression of ENST00000619282m6A in co-cultured cells was detected by MeRIP-qPCR, which showed that the expression of ENST00000619282m6A in co-cultured cells was reduced.

[0046] Figure 5 These are the results of the actinomycin D experiment. The actinomycin D experiment shows that the stability of ENST00000619282 decreases over time after interfering with FTO.

[0047] Figure 6 The effect of ENST00000619282 on cell apoptosis. Interference with ENST00000619282 decreased the expression of pro-apoptotic protein Bax and increased the expression of anti-apoptotic protein Bcl-2 ( Figure 6 AC); overexpression of ENST00000619282 increased the expression of pro-apoptotic protein Bax and decreased the expression of anti-apoptotic protein Bcl-2 ( Figure 6 AC).

[0048] Example 2 Establishment of the downstream target protein PUF60 of ENST00000619282

[0049] 1. Synthesis of Probes

[0050] The biotin-labeled probes of the sense and antisense chains were synthesized by Guangzhou Boxin Biotechnology Co., Ltd., and then the synthesized probe sequences were sequenced and verified. The ENST00000619282 probe sequence required for the experiment is as follows:

[0051]

[0052] 2. Use the RNA pull-down kit to perform RNA pull-down experiments to adsorb proteins that interact with RNA, including extraction of whole cell proteins, removal of nucleic acids and pre-washing of protein samples, formation of RNA secondary structures, preparation of probe-magnetic beads, RNA pull-down, and elution of protein products.

[0053] 3. Protein silver staining detection

[0054] Use the quick silver staining kit to perform silver staining experiments on proteins, prepare SDS-PAGE gel, load samples for electrophoresis, fix, sensitize, silver stain, develop, terminate, and take pictures.

[0055] Figure 7 This is the result of RNA pull down experiment. The results of RNA pull down experiment show that PUF60 is the downstream target gene of ENST00000619282.

[0056] Example 3 Observation of clinical relevance and drug intervention of ENST00000619282 and FTO

[0057] In this example, 30 blood samples from RA patients with a clear diagnosis were collected, and RT-qPCR was used to detect the expression and correlation of ENST00000619282 and FTO in RA, as well as the changes after drug intervention.

[0058] Figure 8 The results of clinical experiments showed that FTO was positively correlated with ENST00000619282 through correlation analysis ( Figure 8 B), after XFC intervention, the expression of ENST00000619282 decreased ( Figure 8 A, C).

[0059] The above contents are merely examples and explanations of the concept of the present invention. The technicians in this technical field may make various modifications or additions to the specific embodiments described or replace them in a similar manner. As long as they do not deviate from the concept of the invention or exceed the scope defined by the claims, they should all fall within the protection scope of the present invention.

Claims

1. An application of methylation modification of long non-coding RNA in the treatment of rheumatoid arthritis, characterized in that: The long non-coding RNA is lncRNA ENST00000619282.

2. Application of methylation modification of long non-coding RNA in the preparation of a drug for treating rheumatoid arthritis, characterized in that: The long non-coding RNA is lncRNA ENST00000619282.

3. Use of methylation modification of long non-coding RNA in the preparation of a drug for treating apoptosis of rheumatoid arthritis cells, characterized in that: The long non-coding RNA is lncRNA ENST00000619282.

4. The use according to claim 1, 2 or 3, characterized in that: The lncRNA ENST00000619282, under the modification of the demethylation transferase FTO, binds to the target protein PUF60 and inhibits cell apoptosis.